- BioGaia and MetaboGen have opened a pilot plant in Eslöv for fermentation.
- The facility will handle manufacturing of traditional lactobacilli and new oxygen-sensitive strains.
- The plant supports clinical studies, process development, and product launch.
- BioGaia now controls the entire development process from early phase to pilot scale manufacturing.
Pilot Plant for New Bacterial Strains
BioGaia, in collaboration with its subsidiary MetaboGen, has opened a pilot plant in Eslöv, Sweden, dedicated to the fermentation of new bacterial strains. This facility aims to advance the clinical development and eventual launch of next-generation probiotic products.
Specialized Manufacturing
The pilot plant is designed to handle the manufacturing of bacteria with varying requirements during fermentation. It can process both traditional lactobacilli and new, extremely oxygen-sensitive strains, ensuring the production of high-quality probiotic products under controlled conditions.
Comprehensive Development Process
The automated and specialized facility will be used for controlled manufacturing, supporting clinical studies, process development, and the launch of new products. This gives BioGaia comprehensive control over the entire development process, from early-phase research to in-house pilot scale manufacturing.
Future Prospects
According to BioGaia's President and CEO, Isabelle Ducellier, the new technology is expected to help the company remain at the forefront of new product formulations. MetaboGen's CEO, Sara Malcus, also expressed optimism about the facility's potential to advance the commercialization of new probiotic products.
